Cancer Treatment and Pharmacogenomics

¹Tertiary Care Hospital, University College London, United Kingdom

²Institute of Microbiology and Molecular Genetics (MMG), University of the Punjab, Lahore, Pakistan

*Corresponding author: Samreen Riaz, Institute of Microbiology and Molecular Genetics (MMG), University of the Punjab, Lahore, Pakistan, Tel: +92 300 435 1979; E-mail: [email protected].

Received Date: February 15, 2023

Published Date: March 09, 2023

Citation: Samreen R, et al. (2023). Cancer Treatment and Pharmacogenomics. Mathews J Cancer Sci. 8(1):38.

Copyrights: Samreen R, et al. © (2023).

ABSTRACT

In cancer, we cannot pick and trial medicines, we only choose medicines after doing genetic studies. Because due to metabolic deficiency, a drug can be toxic to someone. Just like the deficiency of glucose-6-phosphate dehydrogenase. In normal cases, its deficiency is not noticeable because its function is performed by any other enzyme in the body. But if a person with this deficiency takes anti-malarian or some kind of food, RBCs start to lyse, this can result in many complications like kidney failure. Also, this is the only pathway in humans to remove oxidative damage in red blood cells. If oxidative stress occurs in RBCs, oxidation of haemoglobin occurs which results in its functional loss and it attaches with the cell membrane or in the worst cases RBC lyse.

Keywords: Cancer, Pharmacology, RBCs, Toxic, Human.